Provided by Tiger Trade Technology Pte. Ltd.

MiNK Therapeutics, Inc.

11.50
-0.8500-6.88%
Volume:19.89K
Turnover:239.58K
Market Cap:53.98M
PE:-4.04
High:12.38
Open:12.27
Low:11.50
Close:12.35
52wk High:76.00
52wk Low:4.56
Shares:4.69M
Float Shares:1.70M
Volume Ratio:1.20
T/O Rate:1.17%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8431
EPS(LYR):-2.8582
ROE:-1238.98%
ROA:-69.61%
PB:-3.99
PE(LYR):-4.02

Loading ...

Company Profile

Company Name:
MiNK Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
23
Office Location:
149 Fifth Avenue,Suite 500,New York,New York,United States
Zip Code:
10010
Fax:
- -
Introduction:
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Directors

Name
Position
Garo H. Armen
Co-Founder and Chairman
Jennifer S. Buell
Director,Chief Executive Officer and President
Barbara Ryan
Director
Brian Corvese
Director
John Holcomb
Director
Peter Behner
Director
Robert Kadlec
Director
Ulf Wiinberg
Director

Shareholders

Name
Position
Jennifer S. Buell
Director,Chief Executive Officer and President
Christine M. Klaskin
Treasurer,Principal Financial Officer and Principal Accounting Officer